Bellicum Pharma (BLCM) Misses Q4 EPS by 3c

Bellicum Pharma (NASDAQ: BLCM) reported Q4 EPS of ($0.74), $0.03 worse than the analyst estimate of ($0.71).

Bellicum ended the year on December 31, 2016 with cash, restricted cash and investments totaling $113.4 million, compared to $150.4 million at December 31, 2015. In March 2017, Bellicum borrowed the final $10.0 million tranche under its agreement with Hercules Capital. Based on current operating plans, Bellicum expects that current cash resources will be sufficient to meet operating requirements through at least the first quarter of 2018. Projected cash outlays in 2017 include approximately $15 million for capital projects, primarily the completion of the buildout of in-house U.S. manufacturing facilities.

For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance